Prof. Dr. Clemens Schmitt
1 clinical trials · Sponsor
◉ Watch Prof. Dr. Clemens Schmitt
| Record | Firm | Date |
|---|---|---|
| Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 (NCT03129828) | Prof. Dr. Clemens Schmitt | 2017-03-17 |
Track Prof. Dr. Clemens Schmitt automatically
Every clearance here is in the API, with alerts when new ones post.